FDG-PET/CT dokumentované vymizení nekrobiotického xantogranulomu při potlačení tvorby monoklonálního imunoglobulinu bortezomibem, lenalidomidem a dexametazonem Popis případu a přehled literatury o léčbě nekrobiotického xantogranulomu
[Complete remission of necrobiotic xanthogranuloma after disappearance of monoclonal immunoglobulin induced by bortezomib, lenalidomid and dexamethasone]
Language Czech Country Czech Republic Media print
Document type Case Reports, Journal Article
PubMed
35459378
PII: 130096
- Keywords
- Kahler-Pick law, Multiple myeloma, monoclonal gammopathy, necrobiotic xanthogranuloma,
- MeSH
- Bortezomib therapeutic use MeSH
- Dexamethasone therapeutic use MeSH
- Immunoglobulins MeSH
- Humans MeSH
- Multiple Myeloma * complications drug therapy MeSH
- Necrobiotic Xanthogranuloma * complications diagnosis drug therapy MeSH
- Positron Emission Tomography Computed Tomography MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Bortezomib MeSH
- Dexamethasone MeSH
- Immunoglobulins MeSH
Necrobiotic xanthogranuloma (NXG) is a rare chronic condition, belonging to the group non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly monoclonal gammopathy, MGUS and multiple myeloma. The case reported here NXG was diagnosed after 1 years of evolution in patient with asymptomatic multiple myeloma. After treatment with bortezomib, lenalidomid and dexamethasone, there was evident abrupt decrease of monoclonal immunoglobulin to not measurable level (complete remission of multiple myeloma) and in the same time was evident disappearance of cutaneous and hepatic lesions of NXG on FDG-PET/CT. The etiopathogenetic association of monoclonal immunoglobulin with NXG is documented in this case report with disappearance of NXG in the time of disappearance of monoclonal immunoglobulin.
